Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process

Journal of Pharmaceutical and Biomedical Analysis

Volumn 50, Issue 2, 2009, Pages 144-150

  Liu, David Q ^a   Chen, Ted K ^a   McGuire, Michael A ^a   Kord, Alireza S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Analytical control strategy; Genotoxic impurity; Pazopanib hydrochloride; Spiking purging; Trace analysis

Indexed keywords

PAZOPANIB;

ARTICLE; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG PURITY; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION PROCEDURE; PRIORITY JOURNAL; QUALITY CONTROL; ULTRAVIOLET RADIATION; VALIDATION STUDY;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DRUG CONTAMINATION; MASS SPECTROMETRY; MUTAGENS; PYRIMIDINES; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFONAMIDES;

EID: 67349271594     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.04.002     Document Type: Article

References (15)

1. Committee for medicinal products for human use (CHMP), European Medicines Agency (EMEA), London, 28 June 2006 (CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006).
2. Müller L., Mauthe R.J., Riley C.M., Andino M.M., De Antonis D., Beels C., Degeorge J., De Knaep J.A.G.M., Ellison D., Fagerland J.A., Frank R., Fritschel B., Galloway S., Harpur E., Humfrey C.D.N., Jacks A.S., Jagota N., Mackinnon J., Mohan G., Ness D.K., O'Donovan M.R., Smith M.D., Vudathala G., and Yotti L. Regul. Toxicol. Pharmacol. 44 (2006) 198-211
3. US Food and Drug Administration CDER Guidance for industry, http://www.fda.gov/cder/guidance/7834dft.pdf (accessed 14 January 2009).
4. Delaney E.J. Regul. Toxicol. Pharmacol. 49 (2007) 107-124
5. McGovern T., and Jacobson-Kram D. Trends Anal. Chem. 25 (2006) 790-795
6. Xu L.X. Pharm. Res. 25 (2008) 781-791
7. Dobo K.L., Greene N., Cyr M.O., Caron S., and Ku W.W. Regul. Toxicol. Pharmacol. 44 (2006) 282-293
8. Argentine M.D., Owens P.K., and Olsen B.A. Adv. Drug Deliv. Rev. 59 (2007) 12-28
9. Pierson D.A., Olsen B.A., Robbins D.K., DeVries K.M., and Varie D.L. Org. Process Res. Dev. 13 (2009) 285-291
10. Sorbera L.A., Bolós J., and Serradell N. Drugs Future 31 (2006) 585-589
11. An J., Sun M.J., Bai L., Chen T., Liu D.Q., and Kord A. J. Pharm. Biomed. Anal. 48 (2008) 1006-1010
12. Humfrey C.D.N. Toxicol. Sci. 100 (2007) 24-28
13. Mohan C.G., Gandhi T., Garg D., and Shinde R. Mini Rev. Med. Chem. 7 (2007) 499-507
14. Bolt H.M., Foth H., Hengstler J.G., and Degen G.H. Toxicol. Lett. 151 (2004) 29-41
15. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Dimethyl Sulfate, vol. 71, 1999, pp. 575-588.